Citius Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Dec '22 Dec 31, 2022
Net Income	-42.51	-24.76	-21.15	-12.7	0.38
Depreciation & Amortization	2.29	-	-	-	-
Stock-Based Compensation	11.91	8.32	7.5	1.97	-
Other Adjustments	0.56	1.06	0.58	0.58	-0.49
Change in Receivables	-1.08	-	-	-	-
Changes in Inventories	-5.95	-12.65	-2.13	-	-
Changes in Accounts Payable	1.21	9.52	2.42	1.2	-
Changes in Accrued Expenses	15.34	4.09	-0.26	-0.8	0.03
Changes in Other Operating Activities	4.83	8.92	13.17	9.76	0.04
Operating Cash Flow	-16.68	-5.49	0.13	0	-0.05
Purchases of Intangible Assets	-10.75	-5.75	-5	-	-
Other Investing Activities	-	-	-	-	-67.32
Investing Cash Flow	-10.75	-5.75	-5	-	-67.32
Long-Term Debt Issued	-	-	3.8	-	-
Long-Term Debt Repaid	-	-	-	-	-0.13
Net Long-Term Debt Issued (Repaid)	-	-	3.8	-	-0.13
Issuance of Common Stock	30.23	15.17	-	-	69.36
Net Common Stock Issued (Repurchased)	30.23	15.17	-	-	69.36
Other Financing Activities	-	-	1.07	-	-1.57
Financing Cash Flow	30.06	15.17	4.87	-	67.66
Net Cash Flow	2.63	3.92	0	0	0.29
Free Cash Flow	-16.68	-5.49	0.13	0	-0.05
FCF Margin	-297.23%	-	-	-	-
Free Cash Flow Per Share	-0.20	-0.07	0.00	-	-0.03
Levered Free Cash Flow	-24.79	-14.87	-4.15	-2.54	0.31
Unlevered Free Cash Flow	-26.39	-14.68	-7.95	-2.54	-0.07

SEC Filings: 10-K · 10-Q